“Development of novel biomarkers for early cancer detection”
- Growing Adoption of Liquid Biopsy: A significant trend in the North America cancer diagnostics market is the increasing adoption of liquid biopsy techniques. This minimally invasive approach involves analyzing biological samples such as blood, urine, or saliva to detect and monitor cancer.
- For instance, liquid biopsies are being used to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers that provide valuable information about the presence, stage, and genetic profile of cancer. The technique offers several advantages over traditional tissue biopsies, including the ability to obtain real-time information about tumor dynamics, assess treatment response, and detect minimal residual disease.
- The development of advanced technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) has enhanced the sensitivity and specificity of liquid biopsy assays. Moreover, the integration of microfluidic devices and automation platforms is improving the efficiency and throughput of liquid biopsy workflows.
- The increasing focus on personalized medicine and the need for less invasive diagnostic procedures are driving the demand for liquid biopsy solutions. Companies like Roche Diagnostics and Thermo Fisher Scientific are at the forefront of developing and commercializing innovative liquid biopsy technologies.
- The demand for liquid biopsy is growing rapidly across various oncology applications, including early cancer detection, treatment monitoring, and disease recurrence assessment.
